Popiolek K, Bejerot S, Brus O, Hammar Å, Landén M, Lundberg J, Nordanskog P, Nordenskjöld A. Electroconvulsive therapy in bipolar depression -- effectiveness and prognostic factors.

Significant outcomesFour of five patients with bipolar depression were responders to electroconvulsive therapyThe strongest positive prognostic factor for response to ECT was higher age.Patients with psychiatric comorbidities, especially personality disorder and OCD had lower chance to respond to ECT.

 {#acps13075-sec-0006}

LimitationsDiagnosis of bipolar depression was most often based on clinical assessment.Association between pharmacological treatment and response to ECT might be influenced by indication bias.Polypharmacy in majority of patients and dosage of pharmacological agents could have affected associations between pharmacological treatment and outcome.

Introduction {#acps13075-sec-0007}
============

Electroconvulsive therapy (ECT) is an effective treatment option for patients that suffer from severe depression with response rates of 65.8--80% [1](#acps13075-bib-0001){ref-type="ref"}, [2](#acps13075-bib-0002){ref-type="ref"}, [3](#acps13075-bib-0003){ref-type="ref"}, [4](#acps13075-bib-0004){ref-type="ref"}. In clinical practice, ECT is used in both major depressive disorder (MDD) and bipolar depression although the strength of evidence for bipolar depression is lower. Most studies that investigated efficacy of ECT in bipolar depression appear to show no inferiority of ECT in response and remission rates when compared with major depressive disorder [3](#acps13075-bib-0003){ref-type="ref"}, [4](#acps13075-bib-0004){ref-type="ref"}, [5](#acps13075-bib-0005){ref-type="ref"}, [6](#acps13075-bib-0006){ref-type="ref"}, [7](#acps13075-bib-0007){ref-type="ref"}, but there are reports of bipolarity being a prognostic factor of nonresponse to ECT [1](#acps13075-bib-0001){ref-type="ref"}, [8](#acps13075-bib-0008){ref-type="ref"}. Clinical guidelines recommend ECT for patients with MDD and bipolar depression who did not respond to pharmacological therapies and in life threatening cases [9](#acps13075-bib-0009){ref-type="ref"}, [10](#acps13075-bib-0010){ref-type="ref"}, [11](#acps13075-bib-0011){ref-type="ref"}, [12](#acps13075-bib-0012){ref-type="ref"}. However, not all patients respond to ECT, some others have side effects. Hence, it is important to identify patients who benefit from this treatment. The prognostic factors with most convincing evidence are presence of psychotic features [1](#acps13075-bib-0001){ref-type="ref"}, [13](#acps13075-bib-0013){ref-type="ref"}, [14](#acps13075-bib-0014){ref-type="ref"} and shorter episode duration [1](#acps13075-bib-0001){ref-type="ref"}, [5](#acps13075-bib-0005){ref-type="ref"}, [15](#acps13075-bib-0015){ref-type="ref"}, yet not all studies confirm these findings [2](#acps13075-bib-0002){ref-type="ref"}, [16](#acps13075-bib-0016){ref-type="ref"}. Reports concerning other prognostic factors such as age, insufficient response to antidepressants, melancholic features, and symptom severity are more inconsistent. An association between age and response to ECT is relevant as pharmacological treatment in elderly depressed patients are sometimes contraindicated for its side effects. Some studies on patients with unipolar or mixed uni‐ and bipolar samples indicate that older age is a prognostic factor for better ECT efficacy [5](#acps13075-bib-0005){ref-type="ref"}, [13](#acps13075-bib-0013){ref-type="ref"}, [14](#acps13075-bib-0014){ref-type="ref"}, [17](#acps13075-bib-0017){ref-type="ref"}. In other studies, however, age had no significant effect on response to ECT [18](#acps13075-bib-0018){ref-type="ref"}. Pharmacotherapy resistance constitutes nowadays the main indication for ECT, but the influence of baseline medication on response to ECT is unclear. Studies investigated almost exclusively the role of treatment with antidepressants prior to ECT in patients with MDD. Here, previous studies indicate that resistance to antidepressant medication is predictive for inferior response to ECT [19](#acps13075-bib-0019){ref-type="ref"}. Nevertheless, a few newer studies find no relation between resistance to adequate pharmacotherapy and ECT outcome [20](#acps13075-bib-0020){ref-type="ref"}, [21](#acps13075-bib-0021){ref-type="ref"}, [22](#acps13075-bib-0022){ref-type="ref"}. One prospective study investigated the influence of failure of adequate treatment with TCAs and lithium on ECT outcomes and found no such association [22](#acps13075-bib-0022){ref-type="ref"}.

Better understanding of factors that predict higher response to ECT including influence of baseline medication on ECT outcome may lead to better assessment of patients with depression. In particular, there is need of more evidence on the effects among patients with bipolar depression.

Aims of the study {#acps13075-sec-0008}
-----------------

The aim of this study was to examine prognostic factors for response to electroconvulsive therapy in bipolar depression. Also, this study investigated correlations between medication at baseline and response to electroconvulsive therapy. To our knowledge no previous study provides this information.

Material and methods {#acps13075-sec-0009}
====================

Design {#acps13075-sec-0010}
------

This was a register‐based observational study. For the purposes of the study, data from several national registers were compiled. All patients with bipolar depression treated with ECT and assessed with the Clinical Global Impression -- Improvement scale (CGI‐I) [23](#acps13075-bib-0023){ref-type="ref"} were included. A number of clinical variables were selected as possible prognostic factors for ECT response. Univariate and multivariate analyses were conducted to determine associations between variables and response to ECT.

Participants {#acps13075-sec-0011}
------------

All patients in Sweden admitted to a hospital with bipolar depression and treated with ECT between 2011 and 2016 were considered for inclusion in this study (*n* = 1509). CGI‐I score was missing for 258 patients, and these were excluded from the study. In total, 1251 patients entered the study. For patients that were hospitalized more than once during the study period, only the first admission was included in this study.

Data sources {#acps13075-sec-0012}
------------

Data from several national registers were compiled by Statistics Sweden using personal identify number. The Swedish National Patient Register is a mandatory nationwide register of all admissions and outpatient care [24](#acps13075-bib-0024){ref-type="ref"}. It provides information on diagnoses and procedures. Medical conditions are coded according to the International Statistical Classification of Diseases and Related Health Problems -- Tenth Revision. The Swedish National Quality Register for ECT (Q‐ECT) is a nationwide register that collects detailed data about ECT in Sweden. It is a non‐mandatory register with 89% coverage in 2016 [25](#acps13075-bib-0025){ref-type="ref"}. The Longitudinal Integration Database for Health Insurance and Labour Market Studies includes all Swedish residents aged 16 or more and provides detailed information about socio‐economic status including family, employment, education, and income [26](#acps13075-bib-0026){ref-type="ref"}. The Swedish Prescribed Drug Register provides information about all prescribed medicines that are collected at any pharmacy in Sweden [27](#acps13075-bib-0027){ref-type="ref"}.

Variables {#acps13075-sec-0013}
---------

Individuals hospitalized for bipolar depression and receiving ECT were identified from the Swedish National Patient Register (diagnoses F31.3‐5). Information about response to ECT was obtained from the Q‐ECT. Response was quantified using CGI‐I score assessed within 1 week after the completion of ECT. CGI‐I is a seven‐point rating scale that measures the efficacy of treatment. Ratings of one and two indicate "very much improved" and "much improved" respectively. In this study, response was defined as CGI‐I score of one or two. Information about ECT settings and remission was also obtained from the Q‐ECT. Remission was quantified using the Montgomery‐Åsberg Depression Rating Scale Self rated variant (MADRS‐S) [28](#acps13075-bib-0028){ref-type="ref"}, [29](#acps13075-bib-0029){ref-type="ref"} score assessed within 1 week after the completion of ECT and was defined as MADRS‐S score \<10.

Classification of depressive episode in respect of severity was made according to ICD‐10 diagnosis (F31.3, mild to moderate; F31.4, severe without psychotic symptoms; F31.5, severe with psychotic symptoms). Information about comorbid psychiatric conditions was obtained from the Swedish National Patient Register. Information about level of education and cohabiting was obtained from the Longitudinal Integration Database for Health Insurance and Labour Market Studies. Data describing socio‐economic status the year before admission were used when available. Information on level of education the year before admission was missing for eight patients. For two of these eight patients, information on level of education was available for the year of admission, and this was used instead. The remaining six patients were imputed to the largest category. The term "cohabiting" was defined as living with a partner regardless of marital status and/or living with children.

Information about pharmacological treatment prior to index admission was obtained from the Swedish Prescribed Drug Register. Only medicines that were collected within 100 days before the admission were considered. Psychopharmacological agents were divided into the following groups: lithium, lamotrigine, valproate, quetiapine, antidepressants, antipsychotics (all neuroleptics except quetiapine, alimemazine, levomepromazine), anxiolytics (hydroxyzine, promethazine, alimemazine), benzodiazepines, and central stimulants.

ECT settings {#acps13075-sec-0014}
------------

Electroconvulsive therapy was usually administered three times a week using the bidirectional constant‐current brief‐pulse Mecta (Mecta Corp, Lake Oswego, OR, USA) or Thymatron (Somatics Inc., Lake Bluff, IL, USA) devices. The mean number of ECT treatments was 7.0 (standard deviation \[SD\], 3.57; range, 1--38). The electrode application during the first ECT treatment was unilateral for 1141 patients (91.2%), bitemporal for 77 patients (6.2%), bifrontal for 27 patients (2.2%), and not known (data missing) for the remaining six patients. The mean pulse width in the first ECT treatment was 0.5 ms (SD, 0.19 ms), the mean frequency was 70 Hz (SD, 21 Hz), the mean duration was 7.3 s (SD, 1.3 s), the mean current was 838.8 mA (SD, 56.4 mA), and the mean charge was 357 mC (SD, 155 mC).

Statistics {#acps13075-sec-0015}
----------

Logistic regression was used to analyze the association between variables and response to ECT. Age was categorized to identify any non‐linear association with response and was analyzed as continuous variable as well. Analyses were conducted using both univariate and multivariate models. Variables included in multivariate models were as follows: gender, age, level of education, cohabiting, severity of depression, anxiety disorder, substance abuse disorder, personality disorder, obsessive‐compulsive disorder (OCD), attention deficit hyperactivity disorder, autism, history of mania, and psychopharmacological treatment prior to admission. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA) and SPSS 22 (IBM Corp, Armonk, NY, USA).

Ethics statement {#acps13075-sec-0016}
----------------

The study was approved by the regional ethical review board in Uppsala 2014/174. Because this was a register‐based study where patients were not identifiable at any time, patients were not informed of the study and were not asked to provide consent.

Results {#acps13075-sec-0017}
=======

Participants {#acps13075-sec-0018}
------------

Socio‐demographic and clinical characteristics of the study cohort are presented in Table [1](#acps13075-tbl-0001){ref-type="table"}. Of the 1251 patients included in the study, 830 (66.3%) were women. The mean age of the cohort was 52.5 years, median was 53 years (minimum 16 years, maximum 95 years). Most patients (*n* = 593; 47.4%) had high school education, 246 (19.7%) had less than high school education, and 236 (18.9%) had more than 3 years of college education. The majority of patients (*n* = 639; 51.1%) were living alone. Psychiatric comorbidities were common: 319 patients (25.5%) were diagnosed with substance use disorder, 313 (25.0%) with anxiety disorder, and 187 (14.9%) with personality disorder. Comorbid OCD, attention deficit hyperactivity disorder, and autism were less frequent.

###### 

Socio‐demographic and clinical characteristics of the cohort

                                                    All patients *n* = 1251
  ------------------------------------------------- -------------------------
  Gender                                            
  Male                                              421 (33.7)
  Female                                            830 (66.3)
  Age (mean, SD)                                    52.48 (SD 17.04)
  Education                                         
  Less than high school                             246 (19.7)
  High school                                       593 (47.4)
  College \< 3 years                                176 (14.1)
  College ≥ 3 years                                 236 (18.9)
  Cohabiting                                        
  Yes                                               612 (48.9)
  No                                                639 (51.1)
  Severity of depression                            
  Mild or moderate                                  387 (30.9)
  Severe without psychotic symptoms                 642 (51.3)
  Severe with psychotic symptoms                    222 (17.7)
  Comorbidity                                       
  Anxiety disorder                                  313 (25.0)
  OCD                                               33 (2.6)
  Personality disorder                              187 (14.9)
  ADHD                                              68 (5.4)
  Autism spectrum disorder                          22 (1.8)
  Substance abuse disorder                          319 (25.5)
  Admission due to mania prior to index admission   363 (29.0)
  ECT treatment prior to index ECT                  
  Yes                                               537 (42.9)
  No                                                329 (26.3)
  Missing                                           385 (30.8)
  Pharmacotherapy before admission                  
  Antidepressants                                   836 (66.8)
  Lithium                                           473 (37.8)
  Benzodiazepines                                   604 (48.3)
  Antipsychotics                                    541 (43.2)
  Anxiolytics                                       406 (32.5)
  Lamotrigine                                       348 (27.8)
  Quetiapine                                        326 (26.1)
  Valproate                                         170 (13.6)
  Central stimulants                                43 (3.4)

ADHD, attention deficit hyperactivity disorder; ECT, electroconvulsive therapy; OCD, obsessive‐compulsive disorder; SD, standard deviation.
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Psychopharmacological treatments within 100 days prior to ECT {#acps13075-sec-0019}
-------------------------------------------------------------

Antidepressants were used in the 100 days period prior to index admission by 66.8% of patients. Lithium was used by 37.8%, lamotrigine by 27.8%, and valproate by 13.6%. Quetiapine was used by 26.1% of patients, and other neuroleptics were used by 43.2%. Benzodiazepines were used by 48.3% of patients, and anxiolytics by 32.5%. Central stimulants were used by 3.4% of patients.

Response rate and remission {#acps13075-sec-0020}
---------------------------

Of 1251 patients in the study cohort, 1003 (80.2%; 95% confidence interval \[CI\], 77.8--82.2%) were responders to ECT (CGI‐I score of one or two). Patients assessed as CGI‐I 1 (very much improved) and CGI‐I 2 (much improved) constituted 24.4% and 55.8% of total study population respectively. Symptom worsening, quantified as a CGI‐I score of five, six, or seven (minimally, much, or very much worse) within 1 week after ECT, occurred in eight patients (0.6%). MADRS‐S score within 1 week after ECT was available in 606 patients. Of these, 223 (36.8%; 95% CI, 33.2%‐40.8%) achieved remission (MADRS‐S score: 0--9) and 301 (49.7%) had MADRS‐S score 0--12.

Prognostic factors {#acps13075-sec-0021}
------------------

Associations between socio‐demographic and clinical characteristics and response to ECT are summarized in Table [2](#acps13075-tbl-0002){ref-type="table"}. In both univariate and multivariate analysis, patients aged 31--40 years, 61--70 years, or 71‐80 years had higher response rates than patients aged 16--30 years (OR, 2.30; 95% CI, 1.37--3.86; OR, 2.36; 95% CI, 1.47--3.78; and OR, 2.19; 95% CI, 1.15‐4.17 respectively). In univariate analysis, patients in all age categories had significantly higher response rates than patients aged 16--30 years (Fig. [1](#acps13075-fig-0001){ref-type="fig"}). Association between age as a continuous variable and outcome was analyzed, as well. This analysis showed a significant relationship between age and response to ECT in both univariate (OR, 1.02 95% CI, 1.01--1.03; *P* = 0.000) and multivariate models (OR, 1.011; 95% CI, 1.001--1.021; *P* = 0.034). Patients with college education longer than 3 years had a significantly higher response rate to ECT in univariate (OR, 1.75; 95% CI, 1.08--2.83; *P* = 0.022) but not multivariate analysis (OR, 1.54; 95% CI, 0.90--2.61; *P* = 0.113). Patients with severe depression with psychotic symptoms had a higher response rate to ECT (OR, 1.73; 95% CI, 1.11--2.72; *P* = 0.016) than patients with mild or moderate depression; however, this association was not significant in the multivariate analysis. Most investigated psychiatric comorbidities were negative prognostic factors. Comorbid personality disorder or OCD remained a significant negative prognostic factor in the multivariate analysis. Among patients with comorbid personality disorder and comorbid OCD 66.3% respective 54.5% were responders to ECT. Patients treated with lamotrigine before index admission had lower response rates to ECT than patients not treated with lamotrigine. This association remained significant in the multivariate model. Patients treated with antidepressants, antipsychotics, benzodiazepines, or anxiolytics had significantly lower response rates than patients not treated with these medications. However, these associations were no longer significant in the multivariate model. There were no significant associations between response and prior treatment with lithium, valproate, quetiapine, or central stimulants. There was no significant association between response and gender, cohabitation, history of mania, or history of treatment with ECT.

###### 

Results for the logistic regression analysis of predictors of good or very good response to ECT for bipolar depression

                                                                                   *n* (%)       Univariate             Multivariate                       
  -------------------------------------------------------------------------------- ------------- ---------------------- -------------- ------------------- -----------
  Gender                                                                                                                                                   
  Male                                                                             421 (33.7)    Reference                                                  
  Female                                                                           830 (66.3)    1.06 (0.79--1.42)      0.703          1.22 (0.89--1.67)   0.221
  Age, years                                                                                                                                               
  16--30                                                                           165 (13.2)    Reference                                                  
  31--40                                                                           174 (13.9)    2.30 (1.37--3.86)      **0.002**      2.06 (1.18--3.60)   **0.011**
  41--50                                                                           227 (18.1)    1.67 (1.06--2.64)      **0.027**      1.55 (0.95--2.55)   0.082
  51--60                                                                           240 (19.2)    1.66 (1.06--2.61)      **0.026**      1.48 (0.90--2.42)   0.125
  61--70                                                                           245 (19.6)    2.36 (1.47--3.78)      **0.000**      1.96 (1.15--3.35)   **0.014**
  71--80                                                                           150 (12.0)    3.17 (1.77--5.68)      **0.000**      2.19 (1.15--4.17)   **0.018**
  81--95                                                                           50 (4.0)      2.83 (1.19--6.71)      **0.018**      2.33 (0.91--5.94)   0.077
  Education                                                                                                                                                
  Less than high school                                                            246 (19.7)    Reference                                                  
  High school                                                                      593 (47.4)    1.07 (0.75--1.54)      0.711          1.16 (0.78--1.73)   0.452
  Some college \< 3 years                                                          176 (14.1)    0.88 (0.55--1.39)      0.574          0.94 (0.57--1.55)   0.815
  College\>=3 yrs                                                                  236 (18.9)    1.75 (1.08--2.83)      **0.022**      1.70 (1.02--2.84)   0.042
  Cohabiting                                                                                                                                               
  No                                                                               639 (51.1)    Reference                                                  
  Yes                                                                              612 (48.9)    1.28 (0.97--1.70)      0.081          0.80 (0.59--1.09)   0.153
  Severity of depression[†](#acps13075-note-0003){ref-type="fn"}                                                                                           
  Mild or moderate                                                                 387 (30.9)    Reference                                                  
  Severe without psychotic symptoms                                                642 (51.3)    1.09 (0.80--1.48)      0.593          1.07 (0.77--1.47)   0.700
  Severe with psychotic symptoms                                                   222 (17.7)    1.73 (1.11--2.72)      **0.016**      1.43 (0.89--2.29)   0.137
  Substance abuse disorder                                                                                                                                 
  No                                                                               932 (74.5)    Reference                                                  
  Yes                                                                              319 (25.5)    0.69 (0.51--0.94)      **0.017**      0.95 (0.67--1.35)   0.781
  Anxiety disorder                                                                                                                                         
  No                                                                               938 (75.0)    Reference                                                  
  Yes                                                                              313 (25.0)    0.56 (0.418--0.762)    **0.000**      0.82 (0.58--1.16)   0.259
  Personality disorder                                                                                                                                     
  No                                                                               1064 (85.1)   Reference                                                  
  Yes                                                                              187 (14.9)    0.41 (0.29--0.58)      **0.000**      0.59 (0.40--0.87)   **0.008**
  OCD                                                                                                                                                      
  No                                                                               1218 (97.4)   Reference                                                  
  Yes                                                                              33 (2.6)      0.28 (0.14--0.57)      **0.000**      0.35 (0.16--0.76)   **0.008**
  ADHD                                                                                                                                                     
  No                                                                               1183 (94.6)   Reference                                                  
  Yes                                                                              68 (5.4)      0.57 (0.33--0.98)      **0.044**      0.84 (0.41--1.72)   0.631
  Autism spectrum disorder                                                                                                                                 
  No                                                                               1229 (98.2)   Reference                                                  
  Yes                                                                              22 (1.8)      0.43 (0.18--1.02)      0.056          0.93 (0.34--2.51)   0.882
  Admission for mania prior to index ECT[‡](#acps13075-note-0004){ref-type="fn"}                                                                           
  No                                                                               888 (71.0)    Reference                                                  
  Yes                                                                              363 (29.0)    1.00 (0.74--1.36)      0.995          0.99 (0.70--1.40)   0.937
  ECT treatment prior to index ECT                                                                                                                         
  Yes                                                                              537 (42.9)    Reference              0.942          1.20 (0.77--1.64)   0.561
  No                                                                               329 (26.3)    0.99 (0.70--1.39)                                          
  Missing                                                                          385 (30.8)                                                               
  Psychopharmacotherapy prior to index admission                                                                                                           
  Lithium                                                                                                                                                  
  No                                                                               778 (62.2)    Reference                                                  
  Yes                                                                              473 (37.8)    1.084 (0.813--1.447)   0.582          1.20 (0.88--1.63)   0.264
  Lamotrigine                                                                                                                                              
  No                                                                               903 (72.2)    Reference                                                  
  Yes                                                                              348 (27.8)    0.636 (0.473--0.855)   **0.003**      0.70 (0.51--0.96)   **0.027**
  Antipsychotics                                                                                                                                           
  No                                                                               710 (56.8)    Reference                                                  
  Yes                                                                              541 (43.2)    0.697 (0.528--0.922)   **0.011**      0.75 (0.56--1.02)   0.069
  Valproate                                                                                                                                                
  No                                                                               1081 (86.4)   Reference                                                  
  Yes                                                                              170 (13.6)    0.838 (0.566--1.238)   0.374          0.91 (0.59--1.38)   0.640
  Benzodiazepines                                                                                                                                          
  No                                                                               647 (51.7)    Reference                                                  
  Yes                                                                              604 (48.3)    0.692 (0.523--0.915)   **0.010**      0.80 (0.59--1.09)   0.158
  Antidepressants                                                                                                                                          
  No                                                                               415 (33.2)    Reference                                                  
  Yes                                                                              836 (66.8)    0.646 (0.473--0.883)   **0.006**      0.72 (0.51--1.01)   0.059
  Anxiolytics                                                                                                                                              
  No                                                                               845 (67.5)    Reference                                                  
  Yes                                                                              406 (32.5)    0.724 (0.542--0.966)   **0.028**      0.95 (0.69--1.30)   0.742
  Quetiapine                                                                                                                                               
  No                                                                               925 (73.9)    Reference                                                  
  Yes                                                                              326 (26.1)    0.770 (0.567--1.046)   0.094          0.87 (0.62--1.20)   0.400
  Central stimulants                                                                                                                                       
  No                                                                               1208 (96.6)   Reference                                                  
  Yes                                                                              43 (3.4)      0.557 (0.286--1.085)   0.085          1.12 (0.47--2.65)   0.796

Bold values represent *P*‐values \<0.05.

ADHD, attention deficit hyperactivity disorder; CI, confidence interval; ECT, electroconvulsive therapy; OCD, obsessive‐compulsive disorder; OR, odds ratio.

^†^According to International Statistical Classification of Diseases and Related Health Problems -- Tenth Revision (ICD‐10) diagnoses F31.3--F31.5.

^‡^Diagnoses F30.1, F30.2, F30.9, F31.1, F31.2 according to ICD‐10.

John Wiley & Sons, Ltd

![Response to ECT in different age categories expressed as a proportion of patients in each age category.](ACPS-140-196-g001){#acps13075-fig-0001}

Discussion {#acps13075-sec-0022}
==========

In this study, four of five patients are responders to ECT, a result that supports ECT as an effective treatment method for bipolar depression. Furthermore, only eight patients (0.6%) deteriorated in their psychiatric symptoms after ECT (defined as CGI‐I score 5--7). The latest meta‐analysis on this topic [4](#acps13075-bib-0004){ref-type="ref"} reported a pooled response rate to ECT in patients with bipolar depression 77.1% which is consistent with our study.

In this study, several variables were analyzed as the potential prognostic factors for response to ECT. Both univariate and multivariate models are presented (Table [2](#acps13075-tbl-0002){ref-type="table"}). The purpose of that is to present how the model was constructed and to give descriptions of the relationships between variables and response to ECT in univariate models. With the intention of minimizing the effect of confounders we focus on variables that showed significant association with response to ECT in both uni‐ and multivariate models as the most convincing prognostic factors.

The strongest positive prognostic factor for favorable response to ECT was higher age. Earlier studies are inconsistent. van Diermen et al. [14](#acps13075-bib-0014){ref-type="ref"} showed that ECT is more effective in patients at higher age. Haq et al. reported an association between higher age and better response to ECT in their meta‐analysis, but dispute the clinical relevance of this observation. Birkenhäger et al. reported no association between response to ECT and age as a continuous variable, but the youngest age group (18--45 years) had the lowest rate of response. The size of study cohorts and differences in statistical analysis may contribute to the inconsistencies. Comparisons with other studies are difficult as other study cohorts included both unipolar and bipolar depression.

In the current study, comorbid psychiatric disorders were associated with reduced likelihood of responding to ECT. Patients with personality disorder or OCD were significantly less likely to respond to ECT in both univariate and multivariate models. Few studies have investigated the role of comorbidities on ECT outcome. Some indicate that comorbid substance use disorders or personality disorders may negatively affect the outcome of ECT [30](#acps13075-bib-0030){ref-type="ref"}, [31](#acps13075-bib-0031){ref-type="ref"}. Medda et al. [1](#acps13075-bib-0001){ref-type="ref"} reported poorer outcomes for patients with comorbid panic disorder -- agoraphobia but not comorbid social phobia, OCD, or alcohol or drug abuse, but included few patients with comorbidities and the study therefore had limited power to detect differences in outcomes. Our observation that patients with comorbidities had a lower response rate to ECT is in line with studies showing poorer outcomes of medication treatment in patients with psychiatric comorbidities [32](#acps13075-bib-0032){ref-type="ref"}, [33](#acps13075-bib-0033){ref-type="ref"}.

We investigated the impact of medication prior to ECT and observed that patients treated with lamotrigine had significantly lower response rate than those without prior treatment with lamotrigine. One possible explanation is that pharmacological treatment prior to ECT reflects physicians' efforts to alleviate depressive symptoms. Presumably, pharmacological treatment is an indicator for therapy refractory depression in this study population. These results suggest that resistance to pharmacological treatment might be a risk factor for lower response rate to ECT. There is also a possibility that continued use of lamotrigine during ECT might decrease the quality of the seizure, which might also lower the response rate. The impact of medication prior to ECT on response needs further investigations.

Psychotic symptoms were not significantly associated with response to ECT after adjustment to other variables in this study. Previous studies are equivocal as to whether or not presence of psychotic symptoms is an independent predictor of response to ECT. The results may have been confounded by the duration of depressive episode. In the current study, the duration of the depressive episode was not investigated. More studies are needed to evaluate the role of psychosis as a prognostic factor for the outcome of ECT.

In this study 37% of patients achieved remission. Remission rates reported by other investigators vary between 43 and 87% [4](#acps13075-bib-0004){ref-type="ref"}, [34](#acps13075-bib-0034){ref-type="ref"}. Discrepancies between studies can be because of differences in study populations and design. Another possible explanation might be ECT settings. In this study, 91% of patients were treated with right unilateral electrode placement. Superiority of bilateral electrode placement has been suggested by some studies [35](#acps13075-bib-0035){ref-type="ref"}. Yet, a recent meta‐analysis failed to demonstrate significant difference in antidepressant efficacy between high‐dose unilateral and bilateral ECT [36](#acps13075-bib-0036){ref-type="ref"}. Another issue worth consideration is number of treatment sessions. The mean number of sessions in this study was seven. Husain et al. [37](#acps13075-bib-0037){ref-type="ref"} investigated speed of response and showed that 34% of patients achieved remission after six treatments and 65% achieved remission after 10 treatments. This point to longer treatment series could be more beneficial for selected patients. Also, brief pulse width has been suggested as more effective than ultrabrief [38](#acps13075-bib-0038){ref-type="ref"}. In this study the mean pulse width was 0.5 ms. It is possible that more optimal use of ECT, than current Swedish clinical practice, could result in higher remission rates.

In this study, 66.3% of patients treated with ECT were women. This is consistent with other studies. Although there is no difference in the prevalence of bipolar disorder between men and women, women are over‐represented in studies of ECT, probably because of the burden of depressive symptoms. Women with bipolar disorder have more depressive episodes, usually with longer duration [39](#acps13075-bib-0039){ref-type="ref"}.

Among patients considered as participants in this study, 258 were excluded because of missing CGI‐I value. That represent patients that were not included in the Q‐ECT. It is possible that these patients had lower response rate than study population, because centers that include a higher proportion of patients in the Q‐ECT may also provide higher quality of service. It could result in overestimating the effectiveness of ECT.

The present study has several limitations. In most cases, the diagnosis was based on clinical assessment, and it is not known whether or not structured diagnostic methods were used. The information about dosages of pharmacological agents is lacking. The associations between pharmacological treatment and response to ECT may be influenced by indication bias. Multiple adjustments for other variables such as severity of symptoms and presence of psychotic symptoms was done to limit this indication bias. Many patients had been treated with several medicines, and possible interactions between them were not taken into consideration. On the other hand, our findings are strengthened by the large group of patients in the relatively homogenous clinical settings all through Sweden and thus provide a guidance to the clinician\'s decision making regarding ECT.

In conclusion, the present study shows that ECT for bipolar depression was associated with very high response rates. The strongest prognostic factors for better outcome were higher age and the absence of psychiatric comorbidities. This study suggests that resistance to lamotrigine but not to other pharmacological agents might predict lower response rate. Associations between pharmacotherapy prior to ECT and response to ECT need further investigation.
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